Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

Rectal Cancer Clinical Trial

Official title:

Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02935309
• Other study ID #: MCC-18646
• Status: Completed
• Phase: Phase 1
• Start date: October 14, 2016
• Est. completion date: May 14, 2020

Study information

• Verified date: May 2022
• Source: H. Lee Moffitt Cancer Center and Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and what the best dosage is.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: May 14, 2020
• Est. primary completion date: October 11, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically (archival tissue) confirmed adenocarcinoma of the rectum that begins within 12 cm of the anal verge as determined by sigmoidoscopy and/or colonoscopy with no evidence of distant metastasis.

• Locally advanced rectal cancer determined by any of the following features: 1.) Fixed or immobile tumor on physical exam and/or; 2.) T3 disease with invasion through the muscularis propria as defined by transrectal ultrasound, CT or MRI; 3.) T4 disease with invasion of adjacent structures such as pelvic sidewall, sacrum, pelvis, bladder and/or prostate as determined appropriate imaging modalities such as ultrasound, CT or MRI; 4.) Any T with + N on CT scan/MRI or transrectal ultrasound.

• Age equal to or greater than 18 years

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

• Adequate bone marrow, liver and renal function.

• Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.

• Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men should use adequate birth control for at least 3 months after the last administration of lenvatinib.

• Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures.

Exclusion Criteria:

• Cardiac disease: Congestive heart failure > class II New York Heart Association (NYHA). Participants must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.

• Previous pelvic irradiation therapy.

• Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

• Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.

• Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.

• Active clinically serious infection > CTCAE Grade 2.

• Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic, attacks, deep vein thrombosis (DVT) within the past 6 months.

• Bleeding or thrombotic disorders or use of anticoagulants, such as warfarin, or similar agents requiring therapeutic international normalized ration (INR) monitoring. (Treatment with low molecular weight heparin (LMWH) is allowed).

• Active malignancy except for non-melanoma skin cancer or in situ cervical cancer or treated non-pelvic cancer from which the patient has been continuously disease free more than 3 years.

• Marked baseline prolongation of QT/QTc interval (QTc interval = 500 msec) using the Fridericia method (QTc = QT/RR0.33) for QTc analysis.

• Greater than 30 mg/dL on urine analysis. Patients with >30 mg/dL on urine analysis on urine analysis will undergo 24-hour urine collection for quantitative assessment of proteinuria. Patients with 24-hour protein =1 g/24 hours will be ineligible.

• Needing medical attention for serious bleeding in past 4 weeks.

• Previous chemotherapy except for antiangiogenic agent or tyrosine kinase inhibitor (TKI) will be allowed as long as it is more than 5 years.

• Major surgeries within 3 weeks of starting chemotherapy.

• Evidence or history of bleeding diathesis.

• Use of St. John's Wort or rifampin.

• Known or suspected allergy to lenvatinib or any agent given in the course of this trial.

• Any condition that impairs participant's ability to swallow whole pills.

• Any malabsorption problem.

• Medical need for the continued use of potent inhibitors/inducers of CYP3A4.

• Creatinine clearance not within study guidelines.

Related Conditions & MeSH terms

• Adenocarcinoma
• Rectal Adenocarcinoma
• Rectal Cancer
• Rectal Neoplasms

Intervention

Drug:
• Lenvatinib
Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.
• Capecitabine
Pre-surgery Capecitabine, 850 mg/m^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.

Radiation:
• External Radiation Therapy (XRT)
Pre-surgery RT: Participants will receive 6 weeks of radiation therapy. The radiation sessions will be daily, Monday through Friday, except for holidays.

Locations

Country	Name	City	State
United States	H. Lee Moffitt Cancer Center and Research Institute	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
H. Lee Moffitt Cancer Center and Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Rate of Potential Biomarkers for Vascular Endothelial Growth Factor (VEGF)	Investigators will identify potential biomarkers for VEGF pathway and attempt to correlate with pCR. The associations of the potential biomarkers and radiosensitivity index (RSI) with pCR will be examined using logistic regression. A two-sided p-value of <0.05 will be considered statistically significant.	Up to 36 months
Other	Radiosensitivity Index (RSI)	To determine if low radiosensitivity index (RSI) will correlate with pathologic complete response (pCR). pCR will be examined using logistic regression. A two-sided p-value of <0.05 will be considered statistically significant.	Up to 36 months
Primary	Maximum Tolerated Dose (MTD)	MTD of lenvatinib used in combination with capecitabine and external beam radiation as neoadjuvant therapy for patients with locally advanced rectal carcinoma. The MTD of lenvatinib will be defined as the highest dose level at which no more than 1 out of 6 participants experiences dose-limiting toxicity (DLT). DLT: Any of the hematology or non-hematologic toxicities noted in Table 3 of the protocol, considered to be at least possibly related to lenvatinib and/or capecitabine.	Up to 6 months
Secondary	Rate of Pathologic Response	Pathologic response rate after pre-operative therapy and surgery. Pathologic Complete Response (pCR) will be defined as pathologic proof of a complete response based on histologic evaluation of the resected specimen.	Up to 36 months
Secondary	Occurrence of Treatment Related Adverse Events	To further define safety profile of the combination. Adverse events will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0.	Up to 36 months

External Links

•   Moffitt Cancer Center Clinical Trials website